Idexx Laboratories (IDXX) Receivables - Other (2018 - 2026)

Idexx Laboratories (IDXX) has reported Receivables - Other for 9 consecutive years, with $318.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other rose 26.07% year-over-year to $318.7 million; the TTM figure through Mar 2026 stood at $318.7 million (up 26.07% YoY), while the FY2025 annual figure was $312.7 million, up 26.96% from the prior year.
• Receivables - Other came in at $318.7 million for Q1 2026 at Idexx Laboratories, up from $312.7 million in the prior quarter.
• The five-year high for Receivables - Other was $318.7 million in Q1 2026, with the low at $172.6 million in Q1 2022.
• Average Receivables - Other over 5 years is $233.9 million, with a median of $230.0 million recorded in 2024.
• Across the five-year window, Receivables - Other surged 40.78% in 2022 and climbed 9.91% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $190.8 million in 2022, then rose by 16.93% to $223.1 million in 2023, then rose by 10.4% to $246.3 million in 2024, then climbed by 26.96% to $312.7 million in 2025, then advanced by 1.92% to $318.7 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $318.7 million, $312.7 million, and $288.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.